Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors

Journal of Medicinal Chemistry

Volumn 49, Issue 4, 2006, Pages 1271-1281

  Peifer, Christian ^a   Stoiber, Thomas ^b   Unger, Eberhard ^c   Totzke, Frank ^c   Schächtele, Christoph ^c   Marmé, Dieter ^c   Brenk, Ruth ^d   Klebe, Gerhard ^d   Schollmeyer, Dieter ^a   Dannhardt, Gerd ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

^c PROQINASE GMBH   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3,4,5 TRIMETHOXYPHENYL) 4 (3 HYDROXY 4 METHOXYPHENYL) 1H PYRROLE 2,5 DIONE; ANGIOGENESIS INHIBITOR; CYCLIN DEPENDENT KINASE 2; MALEIMIDE DERIVATIVE; PROTEIN KINASE; STAUROSPORINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CHICK EMBRYO; DRUG DESIGN; DRUG INHIBITION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; IC 50; MICROTUBULE ASSEMBLY; MOLECULAR MODEL; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITORS; ANIMALS; BINDING SITES; CHICK EMBRYO; DRUG DESIGN; INDOLES; MALEIMIDES; MODELS, MOLECULAR; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33244469045     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0580297     Document Type: Article

References (53)

1. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
2. Fan, T. D.; Brem, S. In Angiosuppression. The search for new anticancer drugs; Waring, M. J., Ponder, B., Eds.; Kluwer Academic Press: Dordrecht, The Netherlands, 1992; pp 185-229.
3. Yancopoulus, G. D.; Davis, S.; Gale, N. W.; Rudge, J. S.; Wiegand, S. J.; Holash, J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407, 242-248.
4. Tozer, G. M.; Prise, V. E.; Wilson, J.; Locke, R. J.; Vojnovic, B.; Stratford, M. R. L.; Dennis, M. F.; Chaplin, D. J. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999, 59, 1626-1634.
5. Jordan, A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev. 1998, 18, 259-296.
6. Flynn, B. L.; Hamel, E.; Jung, M. K. One-pot synthesis of benzo-[b]furan and indole inhibitors of tubulin polymerization. J. Med. Chem. 2002, 45, 2670-2673.
7. Bibby, M. C. Combretastatin anticancer drugs. Drugs Future 2002, 27 (5), 475-480.
8. Bailly, C.; Bal, C.; Barbier, P.; Combes, P.; Finet, J.-P.; Hildebrand, M.-P.; Peyrot, V.; Wattez, N. Synthesis and biological evaluation of 4-Arylcoumarin analogues of combretastatins. J. Med. Chem. 2003, 46 (25), 5437-5444.
9. Woods, J. A.; Hadfield, J. A.; Pettit, G. R.; Fox, B. W.; McGown, A. T. The interaction with tubulin of a series of stilbenes based on Combretastatin A-4. Br. J. Cancer 1995, 71, 705-711.
10. Gaukroger, K.; Hadfield, J. A.; Hepworth, L. A.; Lawrence, N. J.; McGown, A. T. Novel syntheses of cis and trans isomers of combretastatin A-4. J. Org. Chem. 2001, 66, 8135-8138.
11. Wang, L.; Woods, K. W.; Li, Q.; Barr, K. J.; McCroskey, R. W.; Hannick, S. M.; Gherke, L.; Credo, B. R.; Hui, Y. H.; Marsh, K.; Warner, R.; Lee, J. Y.; Zielinski-Mozng, N.; Frost, D.; Rosenberg, S. H.; Sham, H. L. Potent, orally active Heterocycle-based CA-4 analogues. Synthesis, Structure-Activity Relationship, Pharmacokinetics, and in vivo antitumor activity evaluation. J. Med. Chem. 2002, 45, 1697-1711.
12. Shirai, R.; Takayama, H.; Nishikawa, A.; Koiso, Y.; Hashimoto, Y. Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells. Bioorg. Med. Chem. Lett. 1998, 8, 1997-2000.
13. Medarde, M.; Ramos, A. C.; Pelaez, R.; López, J. L.; Grávalos, D. G.; San Feliciano, A. Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins. Bioorg. Med. Chem. Lett. 1999, 9, 2303.
14. Simoni, D.; Grisolia, G.; Giannini, G.; Roberti, M.; Rondanin, R.; Piccagli, L.; Baruchello, R.; Rossi, M.; Romagnoli, R.; Invidiata, F. P.; Grimaudo, S.; Jung, M. K.; Hamel, E.; Gebbia, N.; Crosta, L.; Abbadessa, V.; Di Cristina, A.; Dusonchet, L.; Meli, M.; Tolomeo, M. Heterocyclic and Phenyl Double-Bond-Locked Combretastatin Analogues Possessing Potent Apoptosis-Inducing Activity in HL60 and in MDR Cell Lines. J. Med. Chem. 2005, 48 (3), 723-736.
15. Moreau, P.; Anizon, F.; Sancelme, M.; Prudhomme, M.; Bailly, C.; Carrasco, C.; Ollier, M.; Severe, D.; Riou, J. F.; Fabbro, D.; Meyer, T.; Aubertin, A. M. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle. J. Med. Chem. 1998, 7, 41 (10), 1631-1640.
16. Gray, N.; Detivaud, L.; Doering, C.; Meijer, L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 1999, 6 (9), 859-875.
17. Davis, P. D.; Hill, C. H.; Lawton, G.; Nixon, J. S.; Wilkinson, S. E.; Hurst, S. A.; Keech, E.; Turner, S. E. Inhibitors of protein kinase C. 1, 2,3-Bisarylmaleimides. J. Med. Chem. 1992, 35 (1), 177-184.
18. Zhang, H.-C.; Ye, H.; Conway, B. C.; Derian, C. K.; Addo, M. F.; Kuo, G. H.; Hecker, L. R.; Croll, J. L.; Westover, L.; Xu, J. Z.; Look, R.; Demarest, K. T.; Andrade-Gordon, P.; Damiano, B. P.; Maryanoff, B. E. 3-(7-Azaindolyl)-4- arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3. Bioorg. Med. Chem. Lett. 2004, 14, 3245-3250.
19. (a) Faul, M. M.; Winneroski, L. L.; Krumrich, C. A. A new one Step Synthesis of maleimides by condensation of glyoxylate esters with acetamides. Tetrahedron Lett. 1999, 40, 1109-1112.
20. (b) Faul, M. M.; Winneroski, L. L.; Krumrich, C. A. A new, efficient method for the synthesis of bisindolylmaleimides. J. Org. Chem. 1998, 63, 6053-6058.
21. Creary, X.; Mehrsheikh-Mohammadi, M. E. Captodative rate enhancements in the methylenecyclopropane rearrangement. J. Org. Chem. 1986, 51, 2664-2668.
22. Bensel, N.; Pevere, V.; Desmurs, J. R.; Wagner, A.; Mioskowski, C. Mesyl guajacol: a versatile intermediate for the synthesis of 5-aminomethyl guajacol and related compounds. Tetrahedron Lett. 2002, 43, 4281-4283.
23. (a) Okauchi, T.; Itonaga, M.; Minami, T.; Owa, T.; Kitoh, K.; Yoshino, H. A general method for acylation of indoles at the 3-position with acyl chlorides in the presence of dialkylaluminium chloride. Org. Lett. 2000, 2 (10), 1485-1487.
24. (b) Ottoni, O.; Neder, A. de V. F.; Dias, A. K. B.; Cruz, R. P. A.; Aquino, L. B. Acylation of indole under Friedel-Crafts conditions- an improved method to obtain 3-Acylindoles regioselectively. Org. Lett. 2001, 3 (7), 1005-1007.
25. Zhang, Z.; Yang, Z.; Wong, H.; Zhu, J.; Meanwell, N. A.; Kadow, J. F.; Wang, T. An effective procedure for the acylation of azaindoles at C-3. J. Org. Chem. 2002, 67, 6226-6227.
26. Bray, B. L.; Mathies, P. H.; Naef, R.; Solas, D. R.; Tidwell, T. T.; Artis, D. R.; Muchowski, J. M. N-(Triisopropylsilyl)pyrrole. A progenitor "par excellence" of 3-substituted pyrroles. J. Org. Chem. 1990, 55, 6317-6328.
27. Tholander, J.; Bergman, J. Syntheses of 6,12-disubstituted 5,11-dihydroindolo[3,2-b]carbazoles, including 5,11-dihydroindolo[3,2-b] carbazole-6,12-dicarbaldehyde, an extremely efficient ligand for the TCDD (Ah) receptor. Tetrahedron 1999, 55 (43), 12577-12594.
28. Pindur, U.; Kim, Y.-S.; Mehrabani, F. Advances in indolo[2,3-a]-carbazole chemistry: design and synthesis of Protein kinase C and topoisomerase-I- inhibitors. Curr. Med. Chem. 1999, 6, 29-69.
29. Reddy, G. M.; Chen, S.-Y.; Uang, B.-J. A facile synthesis of indolo-[2,3-a]pyrrolo[3,4-c]carbazoles via oxidative photocyclization of bisindolylmaleimides. Synthesis 2003, 4, 497-500.
30. Harris, W.; Hill, C. H.; Keech, E.; Malsher, P. Oxidative cyclisations with palladium acetate. A short synthesis of staurosporine aglykon. Tetrahedron Lett. 1993, 34 (51), 8361-8364.
31. Noble, M. E.; Endicott, J. A.; Johnsen, L. N. Science 2004, 303, 1800-1805.
32. Davies, T. G.; Pratt, D. J.; Endicott, J. A.; Johnson, L. N.; Noble, M. E. M. Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol. Ther. 2002, 93, 125-133.
33. Lawrie, A. M.; Noble, M. E.; Tunnah, P.; Brown, N. R.; Johnson, L. N.; Endicott, J. A. Nat. Struct. Biol. 1997, 4, 796-801.
34. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental constructing algorithm. J. Mol. Biol. 1996, 261 (3), 470-489.
35. Sielecki, T. M.; Boylan, J. F.; Benfield, P. A.; Trainor, G. L. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem. 2000, 43, 1-18.
36. Aitkenhead, M.; Christ, B.; Eichmann, A.; Feucht, M.; Wilson, D. J.; Wilting, J. Paracrine and autocrine regulation of vascular endothelial growth factor during tissue differentiation in the quail. Dev. Dyn.1998, 212, 1-13.
37. Vico, P. G.; Kyriacos, S.; Heymans, O.; Louryan, S.; Cartilier, L. Dynamic study of the extraembryonic vascular network of the chick embryo by fractal analysis. J. Ther. Biol. 1998, 195, 525-532.
38. Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13, 9-22.
39. Korpelainen, E. I.; Alitalo, K. Signaling angiogenesis and lymphangiogenesis. Curr. Opin. Cell Biol. 1998, 10, 159-164.
40. Gille, H.; Kowalski, J.; Li, B.; LeCouter, J.; Moffat, B.; Zioncheck, T. F.; Pelletier, L.; Ferrara, N. Analysis of biological effects and signaling properties of Flt-1 (VEGF-R1) and KDR (VEGF-R2). J. Biol. Chem. 2001, 276, 3222-3230.
41. Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 2002, 20 (21), 4368-4380.
42. McGovern, S. L.; Shoichet, B. K. Kinase inhibitors: Not just for kinases anymore. J. Med. Chem. 2003, 46, 1478-1483.
43. Schollmeyer, D.; Peifer, C.; Dannhardt, G. 3-(3,4,5-Trimethoxyphenyl)-4- (3-hydroxy-4-methoxyphenyl)-1H-pyrrole-2,5-dione. Acta Crystallogr. 2005, E61, 604-606.
44. Peifer, C.; Schollmeyer, D.; Dannhardt, G. 3-(Indole-3-yl)-4-(3,4,5- trimethoxyphenyl)-1H-pyrrole-2,5-dione. Acta Crystallogr. 2005, E67, 721-723.
45. Peifer, C.; Schollmeyer, D.; Dannhardt, G. 5,6,7-Trimethoxy-1,2,3,8- tetrahydro-benzo[a]pyrrolo[3,4-c]carbazole-1,3-dione containing one equivalent of DMSO. Acta Crystallogr. 2005, E61, 724-725.
46. SYBYL Molecular Modeling Software. 6.8 ed., Tripos Inc.: St. Louis, MO, 1992.
47. Waldherr-Teschner, M.; Henn, Ch.; Vollhardt, H.; Reiling, S.; Brickmann, J. Texture Mapping: a new tool for molecular graphics. J. Mol. Graphics 1994, 12 (2), 89-105.
48. Böhm, H. J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput.-Aided Mol. Des. 1994, 8 (3), 243-256.
49. Gohlke, H.; Hendlich, M.; Klebe, G. Knowledge-based scoring function to predict protein-ligand interactions. J. Mol. Biol. 2000, 295 (2), 337-356.
50. Lawrie, A. M.; Noble, M. E.; Tunnah, P.; Brown, M. R.; Johnson, L. N.; Endicott, J. A. Nat. Struct. Biol. 1997, 4, 796-801.
51. Peifer, C.; Dannhardt, G. A novel quantitative chick embryo assay as an angiogenesis model using digital image analysis. Anticancer Res. 2004, 24, 3A, 1545-1552.
52. (a) Gaskin, F.; Cantor, C. R.; Shelanski, M. L. Turbidimetric studies of the in vitro assembly and disassembly of porcine neurotubules. J. Mol. Biol. 1974, 89 (4), 737-755.
53. (b) Shelanski, M. L.; Gaskin, F.; Cantor, C. R. Microtubule assembly in the absence of added nucleotides. Proc. Natl. Acad. Sci. U.S.A. 1973, 70, 765-768.